We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Way to Control Drug-Resistant Bacteria

By Biotechdaily staff writers
Posted on 20 Oct 2004
Through serendipity, researchers have found that bacteriophages contain genes that allow them to quickly change their proteins to bind to different cell receptors, a discovery that could lead to genetically engineered phages to treat bacterial infections that have become resistant to antibiotics.

The discovery was made by researchers at the University of California, Los Angeles (UCLA, USA), led by Jeffrey F. More...
Miller, Ph.D., professor and chair of microbiology, immunology, and molecular genetics. Dr. Miller's team was working on another project when they found that the genome of the phage that infects Bordetella bronchiseptica, a relative of the bacterium that causes whooping cough, contains a series of genes that change the part of the virus that binds to the bacterial cell. These genes allow the phage to rapidly evolve new variants that can recognize and attack bacteria that may have become resistant to the previous phage.

"Phage therapy has been practiced for nearly a hundred years in parts of the world, and even in the United States in the first half of the 20th century,” explained Dr. Miller. "But now we think we can engineer bacteriophages to function as ‘dynamic' antimicrobial agents. This could provide us with a renewable resource of smart antibiotics for treating bacterial diseases.”

Dr. Miller and his team are continuing to study this genetic mechanism to learn more about its biochemical properties and to determine whether higher forms of life have similar classes of genes. In time, Dr. Miller believes they will be able to use this knowledge to generate proteins in the laboratory that will bind to almost any molecule of interest. "Without increased understanding of how bacteriophages work, we can potentially tailor these viruses to infect and destroy bacteria that have mutated and become drug-resistant.”




Related Links:
UCLA

New
Gold Member
Aspiration System
VACUSAFE
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
New
Urine Analyzer
respons® UDS100
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.